Alzamend Neuro (ALZN) Stock Price, News & Analysis

Company Overview

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Key Stats

• Today's Range: $1.07 to $1.10
• 50-Day Range: $0.86 to $2.18
• 52-Week Range: $0.84 to $8.22
• Volume: 51,914 shs
• Average Volume: 121,977 shs
• Market Capitalization: $4.19 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.00
• Consensus Rating: Hold

Alzamend Neuro Stock Analysis - MarketRank™

Alzamend Neuro scored higher than 49% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Alzamend Neuro has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Alzamend Neuro has a consensus price target of $28.00, representing about 2,480.6% upside from its current price of $1.09.

Amount of Analyst Coverage

Alzamend Neuro has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Alzamend Neuro are expected to decrease in the coming year, from ($2.58) to ($2.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alzamend Neuro is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alzamend Neuro is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alzamend Neuro has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.62% of the float of Alzamend Neuro has been sold short.

Short Interest Ratio / Days to Cover

Alzamend Neuro has a short interest ratio ("days to cover") of 2.52, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alzamend Neuro has recently decreased by 23.80%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alzamend Neuro does not currently pay a dividend.

Dividend Growth

Alzamend Neuro does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Alzamend Neuro this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 2 people have added Alzamend Neuro to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.5 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $108,388.00 in company stock, which represents 2.6254% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Alzamend Neuro insiders have bought more of their company's stock than they have sold. Specifically, they have bought $108,388.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

1.39% of the stock of Alzamend Neuro is held by insiders.

Percentage Held by Institutions

49.61% of the stock of Alzamend Neuro is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALZN Stock Analysis - Frequently Asked Questions

How have ALZN shares performed this year?

Alzamend Neuro's stock was trading at $1.82 on January 1st, 2026. Since then, ALZN shares have decreased by 40.4% and is now trading at $1.0850.

How were Alzamend Neuro's earnings last quarter?

Alzamend Neuro, Inc. (NASDAQ:ALZN) posted its quarterly earnings results on Wednesday, March, 11th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by $0.05.

When did Alzamend Neuro's stock split?

Alzamend Neuro shares reverse split on Tuesday, July 16th 2024.The 1-10 reverse split was announced on Tuesday, July 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Alzamend Neuro IPO?

Alzamend Neuro (ALZN) raised $12 million in an initial public offering on the week of June 14th 2021. The company issued 2,500,000 shares at a price of $5.00 per share. Spartan Capital Securities, LLC served as the underwriter for the IPO and -- was co-manager.

How do I buy shares of Alzamend Neuro?

Shares of ALZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Alzamend Neuro own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alzamend Neuro investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), Predictive Oncology (POAI), AST SpaceMobile (ASTS), NIO (NIO) and Ford Motor (F).

Company Calendar

• Last Earnings: 3/11/2026
• Today: 5/06/2026
• Fiscal Year End: 4/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALZN
• CIK: 1677077
• Web: www.alzamend.com
• Phone: 844-722-6303
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Alzamend Neuro: $28.00
• High Price Target: $28.00
• Low Price Target: $28.00
• Potential Upside/Downside: +2,445.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.51 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -177.52%
• Return on Assets: -140.41%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.99
• Quick Ratio: 1.99

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.95 per share
• Price / Book: 0.22

Miscellaneous

• Outstanding Shares: 3,805,000
• Free Float: 3,752,000
• Market Cap: $4.19 million
• Optionable: No Data
• Beta: 0.11